Title:
PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVE
Document Type and Number:
WIPO Patent Application WO/2023/027198
Kind Code:
A1
Abstract:
The present invention provides a preparation for oral administration containing a triazine derivative that exhibits a viral proliferation inhibiting action.
Inventors:
GOMI MASATO (JP)
HORIUCHI KENSUKE (JP)
MORIMOTO MASAYUKI (JP)
TAKAGAKI KEISUKE (JP)
HORIUCHI KENSUKE (JP)
MORIMOTO MASAYUKI (JP)
TAKAGAKI KEISUKE (JP)
Application Number:
PCT/JP2022/043092
Publication Date:
March 02, 2023
Filing Date:
November 22, 2022
Export Citation:
Assignee:
SHIONOGI & CO (JP)
International Classes:
A61K31/53; A61K9/20; A61K31/194; A61K47/32; A61K47/38; A61P11/00; A61P31/12; A61P31/14; A61P43/00; C07D403/14
Domestic Patent References:
| WO2022138988A1 | 2022-06-30 | |||
| WO2012020749A1 | 2012-02-16 | |||
| WO2010092966A1 | 2010-08-19 | |||
| WO2012020749A1 | 2012-02-16 | |||
| WO2013089212A1 | 2013-06-20 | |||
| WO2010092966A1 | 2010-08-19 | |||
| WO2014200078A1 | 2014-12-18 | |||
| WO2012009258A2 | 2012-01-19 | |||
| WO2021205298A1 | 2021-10-14 | |||
| WO2021250648A1 | 2021-12-16 |
Foreign References:
| CN113620888A | 2021-11-09 | |||
| CN113666914A | 2021-11-19 | |||
| CN113735838A | 2021-12-03 | |||
| CN113773300A | 2021-12-10 | |||
| CN113801097A | 2021-12-17 |
Other References:
UNOH YUTO, UNOH YUTO, UEHARA SHOTA, NAKAHARA KENJI, NOBORI HARUAKI, YAMATSU YUKIKO, YAMAMOTO SHIHO, MARUYAMA YUKI, TAODA YOSHIYUKI: "Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 65, no. 9, 12 May 2022 (2022-05-12), US , pages 6499 - 6512, XP093007183, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.2c00117
OLUBIYI OLUJIDE O., OLAGUNJU MARYAM, KEUTMANN MONIKA, LOSCHWITZ JENNIFER, STRODEL BIRGIT: "High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2", MOLECULES, vol. 25, no. 14, pages 3193, XP055944494, DOI: 10.3390/molecules25143193
AKAJI KENICHI, KONNO HIROYUKI: "Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease", MOLECULES, vol. 25, no. 17, pages 3920, XP055826867, DOI: 10.3390/molecules25173920
LIU YUZHI; LIANG CHENGYUAN; XIN LIANG; REN XIAODONG; TIAN LEI; JU XINGKE; LI HAN; WANG YONGBO; ZHAO QIANQIAN; LIU HONG; CAO WENQIA: "The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 206, 6 August 2020 (2020-08-06), AMSTERDAM, NL , XP086299093, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2020.112711
"COVID-19 Dashboard by the Center for Systems Science and Engineering at Johns Hopkins University", 21 September 2022, JOHNS HOPKINS UNIVERSITY
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 382, 2020, pages 1564 - 1567
"Report of the WHO-China Joint Mission on Coronavirus disease 2019 (COVID-19", 28 February 2020, WHO
SCIENCE, vol. 300, 2003, pages 1763 - 1767
"A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF'-00835231 as a potential new treatment for COVID-l_9", JOURNAL OF VIROLOGY, 26 April 2021 (2021-04-26), Retrieved from the Internet
CELL RESEARCH, vol. 30, 2020, pages 678 - 692
SCIENCE, vol. 368, 2020, pages 409 - 412
A(ΗS CENTRAL SCIENCE, vol. 7, no. 3, 2021
CANCER TREATMENT REVIEWS, vol. 11, 1984, pages 99 - 110
CONTRIBUTIONS TO ONCOLOGY, vol. 18, 1984
ARZNEIMITTEL-FORSCLMNG, vol. 6, 1984, pages 663 - 668
261ST AM CHEM SOC (ACS) NATL MEET, 5 April 2021 (2021-04-05)
SCIENCE, vol. 374, 2021, pages 1586 - 1593
"Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89°,% In Interim Analysis Of Phase 2/3 EPIC-HR Study", 5 November 2021, PFIZER PRESS RELEASE
AIMECS 2021 (AFMC INTERNATIONAL MEDICINAL CHEMISTRY SYMPOSIUM 2021, 2 December 2021 (2021-12-02)
"Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19", BIORXIV, Retrieved from the Internet
"Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19", J. MED. CHEM., vol. 65, 2022, pages 6499 - 6512
"Isotopes in the Physical and Biomedical Sciences", vol. 1, 1987, article "Labeled Compounds"
SAKURAI TOSHIO: "Manual of X-ray structural analysis", 1983, SHOKABO CO., LTD.
STOUTJENSEN: "X-Ray Structure Determination: A Practical Guide", 1968, MACMILLAN CO.
ATHERTON, E.SHEPPARD, R. C.: "In Solid Phase Peptide Synthesis, A Practical Approach", 1989, IRL PRESS AT OXFORD UNIVERSITY PRES
BIOORG. MED. CHEM., vol. 5, 1997, pages 1883 - 1891
"Japanese Pharmacopoeia"
OLUBIYI OLUJIDE O., OLAGUNJU MARYAM, KEUTMANN MONIKA, LOSCHWITZ JENNIFER, STRODEL BIRGIT: "High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2", MOLECULES, vol. 25, no. 14, pages 3193, XP055944494, DOI: 10.3390/molecules25143193
AKAJI KENICHI, KONNO HIROYUKI: "Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease", MOLECULES, vol. 25, no. 17, pages 3920, XP055826867, DOI: 10.3390/molecules25173920
LIU YUZHI; LIANG CHENGYUAN; XIN LIANG; REN XIAODONG; TIAN LEI; JU XINGKE; LI HAN; WANG YONGBO; ZHAO QIANQIAN; LIU HONG; CAO WENQIA: "The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 206, 6 August 2020 (2020-08-06), AMSTERDAM, NL , XP086299093, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2020.112711
"COVID-19 Dashboard by the Center for Systems Science and Engineering at Johns Hopkins University", 21 September 2022, JOHNS HOPKINS UNIVERSITY
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 382, 2020, pages 1564 - 1567
"Report of the WHO-China Joint Mission on Coronavirus disease 2019 (COVID-19", 28 February 2020, WHO
SCIENCE, vol. 300, 2003, pages 1763 - 1767
"A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF'-00835231 as a potential new treatment for COVID-l_9", JOURNAL OF VIROLOGY, 26 April 2021 (2021-04-26), Retrieved from the Internet
CELL RESEARCH, vol. 30, 2020, pages 678 - 692
SCIENCE, vol. 368, 2020, pages 409 - 412
A(ΗS CENTRAL SCIENCE, vol. 7, no. 3, 2021
CANCER TREATMENT REVIEWS, vol. 11, 1984, pages 99 - 110
CONTRIBUTIONS TO ONCOLOGY, vol. 18, 1984
ARZNEIMITTEL-FORSCLMNG, vol. 6, 1984, pages 663 - 668
261ST AM CHEM SOC (ACS) NATL MEET, 5 April 2021 (2021-04-05)
SCIENCE, vol. 374, 2021, pages 1586 - 1593
"Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89°,% In Interim Analysis Of Phase 2/3 EPIC-HR Study", 5 November 2021, PFIZER PRESS RELEASE
AIMECS 2021 (AFMC INTERNATIONAL MEDICINAL CHEMISTRY SYMPOSIUM 2021, 2 December 2021 (2021-12-02)
"Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19", BIORXIV, Retrieved from the Internet
"Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19", J. MED. CHEM., vol. 65, 2022, pages 6499 - 6512
"Isotopes in the Physical and Biomedical Sciences", vol. 1, 1987, article "Labeled Compounds"
SAKURAI TOSHIO: "Manual of X-ray structural analysis", 1983, SHOKABO CO., LTD.
STOUTJENSEN: "X-Ray Structure Determination: A Practical Guide", 1968, MACMILLAN CO.
ATHERTON, E.SHEPPARD, R. C.: "In Solid Phase Peptide Synthesis, A Practical Approach", 1989, IRL PRESS AT OXFORD UNIVERSITY PRES
BIOORG. MED. CHEM., vol. 5, 1997, pages 1883 - 1891
"Japanese Pharmacopoeia"
Attorney, Agent or Firm:
SUGITA Ken-ichi et al. (JP)
Download PDF: